• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Rufinamide oral suspension approved for seizures

Article

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.

The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy.

Lennox-Gastaut syndrome usually begins before 4 years of age as a result of brain malformations, severe head injury, perinatal asphyxia, central nervous system infection, or inherited degenerative or metabolic disorders. Patients may experience frequent seizures. One-third of cases present with no perceivable causes.

Children with LGS display developmental delays and impaired intellectual function, information processing, and behavior.

Rufinamide is approved for children 4 years of age and older and adults. The new oral suspension benefits patients who prefer a liquid or who find tablets difficult to swallow.

Related Videos
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
Steven Selbst, MD
© 2024 MJH Life Sciences

All rights reserved.